European regulators have granted Sanofi CE mark approval for its JuniorSTAR insulin pen, designed for use in type 1 diabetes patients 6 to 18 years of age. The reusable device supports half-unit dosing increments and works with Insuman, Lantus and Apidra, allowing more insulin dosing flexibility for health care providers.
EU approves half-unit insulin pen from Sanofi
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||